The Chronic Kidney Disease Drugs Market, estimated at USD 15.92 Bn in 2025, is expected to exhibit a CAGR of 5.4% and reach USD 23.02 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Market Dynamics:
Global chronic kidney disease drugs market growth is primarily driven by two key factors:
Rising prevalence of diabetes: Diabetes is one of the leading causes of CKD globally. As per WHO, the number of diabetes patients had increased from 108 million in 1980 to 422 million in 2014. High blood sugar levels caused by diabetes can damage kidneys over time leading to CKD.
Growing geriatric population: Older population aged 60 years or above is more susceptible to developing CKD due to age-related decline in kidney functions. According to UN Data, number of people aged 60 years or above is projected to double from 12% to 22% between 2015 and 2050. This expands the target patient pool and subsequently increases demand for CKD drugs.
Increasing Prevalence of Chronic Kidney Disease Can Drive Market Growth
Rising prevalence of chronic kidney disease (CKD) across the globe can drive the chronic kidney disease drugs market growth. According to the National Kidney Foundation, more than 10% of the global population is currently affected by CKD. Factors such as the rising geriatric population, increasing incidence of diabetes and hypertension, and growing obesity rates have significantly contributed to rising CKD burden. With no known cure for CKD currently available, patients rely on disease management medications to delay the progression of kidney damage. This growing patient pool boosts demand for CKD drugs.
Growing Awareness and Diagnosis Rates Drives Market Growth
Global chronic kidney disease drugs market growth is driven by rising awareness and improved diagnosis rates of CKD globally. Various government and private organizations are undertaking initiatives to educate people about kidney health and the importance of regular screening. This helps to detect CKD at an early stage when treatment can be most effective. Furthermore, the development of advanced diagnostic tools has made it easier for healthcare practitioners to identify CKD. Increasing number of CKD cases being diagnosed and treated boosts demand for associated drugs and therapeutics.
High Cost of Treatment Can Pose Challenges
High cost of CKD treatment can hamper the market growth. Drug therapy forms an important part of CKD management. However, most CKD drugs are expensive, thus, making long-term medication adherence a significant challenge, especially in cost-sensitive developing regions. Without proper treatment, CKD can rapidly progress to end-stage renal disease, requiring costly renal replacement therapies like dialysis or kidney transplantation. The high economic burden on patients limiting their access to quality care is a major encumbrance to the chronic kidney disease drugs industry.
Limited Healthcare Infrastructures Hinders Market Penetration
Lack of adequate healthcare infrastructure and resources in many underdeveloped and developing economies to efficiently diagnose and manage CKD can hamper the market growth. These regions have insufficient number of nephrologists and dialysis centers. Their healthcare systems have low allocation for non-communicable diseases like CKD. The limited access to proper diagnostic, preventive and curative services is restricting the penetration of CKD drugs in such areas, thus, negatively impacting the market growth.
Increasing Outsourcing of Clinical Trials Present Lucrative Opportunities
Rising outsourcing of R&D activities and clinical trials to CROs (contract research organizations) based in Asia Pacific and Latin American countries can offer opportunity for chronic kidney disease drug makers. This trend allows companies to achieve significant cost savings while tapping into the large patient pools in these regions. It also help foster clinical research in new geographies. The emerging markets with their growing biotech industries present a lucrative platform for pharmaceutical players to conduct trials and launch new products. Collaborations with Low-Cost Generic Producers Holds Potential
Increasing collaborations between innovator drug companies and low-cost generic producers from India and China can offer growth opportunities. Given the economic burden of CKD treatment, partnerships allowing supply of affordable biosimilars and generics present significant market penetration opportunities in price-sensitive regions. By ensuring access to off-patent medications at low prices, these tie-ups are paving the way for uptake in underpenetrated areas, thus, expanding the scope for branded drugs as well.
Link - https://www.coherentmarketinsights.com/market-insight/chronic-kidney-disease-drugs-market-1713
Key Developments:
- On August 8, 2024, Novartis announced that the FDA had granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor, for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Fabhalta targets the alternative complement pathway, which is implicated in IgAN when overactivated in the kidneys.
- In July 2024, Ardelyx, Inc., in partnership with the American Association of Kidney Patients and the National Minority Quality Forum, had filed a lawsuit against the U.S. Department of Health and Human Services and CMS. The lawsuit challenges CMS’s plan to include XPHOZAH (tenapanor) and other oral phosphate-lowering therapies in the end-stage renal disease prospective payment system, arguing it will adversely affect patient access to these crucial medications.
- In July 2024, Renalys Pharma initiated its Phase III clinical trial for sparsentan in Japan, targeting IgA nephropathy. The trial, which is a multicenter, open-label study involving around 30 Japanese patients, aims to confirm the drug's efficacy and safety. Results are anticipated in the second half of 2025, supporting a potential approval submission to the Pharmaceuticals and Medical Devices Agency (PMDA).
- In June 2024,FibroGen, Inc. announced that the FDA had cleared its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors with high Gal9 expression. CEO Thane Wettig highlighted the milestone as a key step in advancing their oncology pipeline. FG-3165 has shown anti-tumor activity and good safety in preclinical studies.
Key Player:
AstraZeneca, Amgen Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi, GlaxoSmithKline plc (GSK), AbbVie Inc., Keryx Biopharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd., Regeneron Pharmaceuticals, Inc., Bayer AG, Reata Pharmaceuticals, Inc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Akebia Therapeutics, Inc.
Contact Us